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A B S T R A C T
Background: Molecules of the innate immune response are increasingly recognized as important mediators in
allograft injury during and after kidney transplantation. We therefore aimed to establish the relationship be-
tween the expression of these genes at implantation, during an acute rejection (AR) and on graft outcome.
Methods: A total of 19 genes, including Toll like receptors (TLRs), complement components and regulators, and
apoptosis-related genes were analyzed at the mRNA level by qPCR in 123 biopsies with acute rejection and
paired pre-transplantation tissue (n= 75).
Results: Before transplantation, relative mRNA expression of BAX:BCL2 ratio (apoptosis marker) and several
complement genes was significantly higher in tissue samples from deceased donors compared to living donors.
During AR, TLRs and complement genes showed an increased expression compared to pre-transplant conditions,
whereas complement regulators were decreased. A relatively high TLR4 expression level and BAX:BCL2 ratio
during AR in the deceased donor group was associated with adverse graft outcome, independently of clinical risk
factors.
Conclusions: Complement- and apoptosis-related gene expression is elevated in deceased donor transplants be-
fore transplantation. High BAX:BCL2 ratio and TLR4 expression during AR may reflect enhanced intragraft cell
death and immunogenic danger signals, and pose a risk factor for adverse graft outcome.
1. Introduction
The occurrence of an acute kidney allograft rejection, associated
with infiltration of recipient immune cells to the kidney, is a risk factor
for adverse graft outcome [1]. The role of innate immunity including
pattern recognition receptors and the complement system in rejection
has been appreciated [2,3]. Toll like receptors (TLRs) are a family of
transmembrane proteins that are capable of recognizing pathogen-as-
sociated molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs) [4]. TLR stimulation leads to dendritic cell matura-
tion, characterized by upregulation of pro-inflammatory cytokines,
chemokines, and co-stimulatory molecules, which initiate an immune
response [5]. Endogenous ligands including heat-shock proteins (HSP)
[6], uric acid [7], high-mobility group box 1 protein (HMGB1) [8,9],
and genomic double-stranded DNA [10] may stimulate TLRs. The in-
teraction between HMGB1 and TLR4 leads to proinflammatory re-
sponses in the graft: after kidney transplantation, recipients with a
donor graft containing a genotype variant in the coding sequence of
TLR4 had lower expression of proinflammatory genes MCP-1 and TNFα
and higher expression of anti-inflammatory heme oxygenase 1, and
they showed an increased rate of immediate graft function [11]. As-
sociation of TLR2 and TLR4 expression was found with renal ischemia
reperfusion injury (IRI) and early kidney allograft outcomes [12,13].
Other TLRs have not been investigated in the context of delayed graft
function (DGF) and acute rejection (AR).
The complement system plays a pivotal role in ischemia reperfusion
injury and allograft rejection after transplantation [3]. The expression
of complement components is significantly increased in deceased donor
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kidneys after cold ischemia [14,15]. Activation of the complement
cascade leads to the release of anaphylatoxins (C3a and C5a) and the
formation of the membrane attack complex (MAC) C5b–C9, which
mediates the injury following transplantation [16,17]. C2 and C4 are
essential components in the classical and lectin pathway, and C3 plays a
central role in all pathways of the complement system. Complement
regulators act as inhibitors of the complement cascade through various
mechanisms [18,19]. For example, the decay acceleration factor
(CD55) prevents the formation of C3 convertase. CD46 acts as cofactor
for inactivating C3b and C4b by serum factor I. Complement receptor 1
both has decay-accelerating activity and cofactor activity. CD59 pre-
vents the formation of MAC. Deficiency of CD55 and CD59 in experi-
mental settings leads to increased renal ischemia reperfusion injury
[20,21]. In C4d-negative biopsy specimens during allograft dysfunction
local CD55 expression was related to favorable transplant outcome
[22].
The role of apoptosis in IRI after kidney transplantation is increas-
ingly being recognized [23,24]. The anti-apoptotic protein B-cell lym-
phoma 2 (BCL2) was significantly decreased and pro-apoptotic protein
BCL2-associated X protein (BAX) was increased during normothermic
ischemia [25]. The augmentation of BCL2 protects renal tubular cells
from IRI through reducing renal tubular epithelial cell apoptosis [26].
High ratios of BAX:BCL2 in pre-transplant biopsies are associated with
an increased risk of DGF [27].
In the present study, we examined innate-immune-related and
apoptosis-related markers in kidney biopsies of 125 patients before
transplantation and during an acute rejection episode, and investigated
their relation to clinical outcome.
2. Methods
2.1. Patient characteristics
Patients who had received a kidney allograft at the Leiden
University Medical Center (LUMC) during 1995–2005 were included. A
total of 123 for-cause biopsy samples in case of clinical suspicion of AR
were obtained within 6months after transplantation, and 77 pre-
transplantation biopsies (75 biopsies paired to the subsequent AR
biopsy) were taken at time of transplantation before reperfusion.
Patient characteristics are shown in Table 1. Delayed graft function was
defined as dialysis-dependency in the first week after transplantation.
2.2. Ethics
Written informed consent was obtained from donors for use of part
of the human material for scientific purposes. The study were per-
formed in accordance with the Declaration of Helsinki Good Clinical
Guidelines and approved by the local medical ethics committee.
2.3. Gene selection
The innate immune related genes (TLR1-TLR10), potentially acting
as initiators of inflammation, were studied. The key complement
component (C2, C3, C4) and complement regulators (CR1, CD46, CD55,
CD59), which inhibit complement activation, were included. The
apoptosis related genes BAX and BCL2, which may be associated with
IRI and DGF, were also tested.
2.4. RNA extraction and cDNA synthesis
RNA isolation and quality check, and cDNA synthesis were per-
formed as described previously [28].
2.5. Real time quantitative PCR analysis
Optimal primers pairs were selected using Primer 3 version 4.0.0.
To prevent amplification of genomic DNA, reverse and forward primers
were designed to target separate exons, spanning at least one intron
with a size of 800 bp or more. All primer sets were tested on control
cDNA, and PCR efficiencies were between 90% and 110%. The 15-μL
qPCR reaction contained 3 μL of 25-times-diluted cDNA, 15 pmol for-
ward and reverse primers, 7.5 μL of PCR Mix (Applied Biosystems by
Life Technologies, Austin, Texas, USA), and nuclease-free water [29].
Relative gene expression levels were normalized to the geometric mean
of the reference genes β-actin and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH).
2.6. Immunohistochemistry
Immunohistochemical studies were performed on an independent
set of 34 formalin-fixed and paraffin-embedded (FFPE) kidney biopsy
samples: 25 from patients with AR and 9 protocol biopsies from patients
with stable graft function. Patients included in this group were trans-
planted between 2006 and 2015. Monoclonal anti-human antibodies
against BAX (ab32503, Abcam, 1:1400 dilution), BCL2 (Sp66,
Ventana), TLR4 (ab22048, Abcam, 1:800 dilution), and TLR9 (clone
26C593.2, Novus, 1:800 dilution) were used for immunohistochemistry
on sequential 4-μm sections. Staining procedures have been described
in a previous publication [30]. Semi quantitative scoring of the number
of BCL2-, TLR4-, and TLR9 positive tubular epithelial cells was per-
formed blindly by two observers using a scale from 0 to 5 (0=0%,
1≤ 10%, 2=10–25%, 3= 26–50%, 4=51–75%, 5=76–100%).
2.7. Statistical analyses
Gene expression differences in paired (PreTx, AR) tissue samples
were analyzed using Wilcoxon signed ranks test. Differences in gene
expression between deceased and living donors and the occurrence of
DGF were assessed by Mann-Whitney U tests (two-sided). Correlations
between innate immunity mRNA expression levels and mRNA
Table 1
Demographics of patient cohort.
Variable Number (%)
Recipient age (≥ 50 years) 53 (43.1%)
Recipient gender (Female) 40 (32.5%)
Donor age (≥ 50 years) 52 (42.6%)
Donor gender (Female) 74 (60.7%)
Donor type (Living) 24 (19.5%)
Time from transplant to rejection (days, IQR) 14 (9–37)
First transplantation (Yes) 103 (84.4%)
HLA–A/B matching (Yes) 20 (16.4%)
HLA-DR matching (Yes) 43 (35.2%)
Virtual PRA (0–5%) 81 (66.4%)
DGF (Yes) 33 (28.7%)
Steroid responsiveness 68 (56.2%)
Cold ischemia time (≤ 18 h) 31 (29.8%)
Banff score
Glomerulitis (g= 0/1/2/3) 74/25/7/3
Interstitial inflammation (i= 0/1/2/3) 5/44/36/24
Tubulitis (t= 0/1/2/3) 11/39/38/21
Intimal arteritis (v= 0/1/2/3) 62/24/7/7
Interstitial fibrosis (ci= 0/1/2) 61/41/7
Tubular atrophy (ct= 0/1/2) 60/44/5
C4d diffuse positive 14 (11.4%)
Rejection characteristics
No rejection 7 (5.7%)
Borderline rejection 33 (27.0%)
Interstitial rejection 42 (34.4%)
Vascular rejection 40 (32.8%)
Graft survival (Death censored)
> 1 year 106 (92.2%)
> 6 year 101 (87.8%)
HLA, human leukocyte antigen; PRA, panel reactive antibodies; DGF, delayed graft
function.
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expression of general inflammation markers were analyzed by
Spearman's rank correlation coefficients (two-sided). The Bonferroni
method was used to correct for multiple comparisons. Death-censored
graft survival curves were created using the Kaplan-Meier method, and
differences between curves were calculated using log rank tests. High
expression level of inflammatory markers (CD163, CD68, CD20, CD3e)
was defined as recipients with deceased donor graft with the highest
one-third of gene expression. Risk factors affecting graft survival in the
deceased donor group were analyzed by multivariate Cox-regression
model including the variables showed a borderline significance
(P < 0.1) in univariate test. Statistical analyses were performed using
SPSS statistics, version 23. Due to the limited number of graft loss
events, penalized survival analysis by lasso method, including clinical
and molecular risk factors, were performed using the “penalized” R
(3.4.0 version) package [31].
3. Results
3.1. Relation of pre-transplant gene expression levels with the type of donor
No significant difference was observed between deceased (n= 65)
and living (n=11) donors regarding the donor age and donor gender.
A shorter cold ischemia time (< 18 h) was more frequently seen in the
living-related donation group. Sixteen genes, including the TLRs and
membrane-bound complement regulators C4 and BAX, were not sig-
nificantly different in their expression between living and deceased-
related donors at t0 (Table 2). The expression of the complement genes
C2 and C3 was>4-fold higher in the cadaveric donors compared to the
living-related donors (Table 2). A significantly higher BAX:BCL2 ratio
was observed in biopsies of deceased donor kidneys compared to living-
related donor kidneys (Fig. 1). Within the deceased donation group,
recipients with relatively high expression of C2, C3 and BAX:BCL2 did
not differ from recipients with relatively low expression in the in-
cidence of DGF, steroid resistant rejection, and graft survival (data not
shown).
3.2. No association of gene expression before transplantation with delayed
graft function
All recipients with DGF (28.7%) had received a deceased donor
renal allograft. Donor age of> 50 years was a risk factor for DGF. In the
pre-implantation tissue of deceased donors, none of the genes in-
vestigated were significantly different in expression between patients
with DGF and those with no DGF (Table 2).
3.3. Comparison of pre-transplant and acute rejection tissues
Paired pre-transplant and acute rejection biopsies of 75 patients
were available for analysis of gene expression dynamics (Table 3). The
expression level of TLR6, TLR7, TLR8, TLR9, and TLR10 was ele-
vated>5.5 fold at the moment of AR, and the expression levels of
TLR1, TLR2, TLR3, and C2 were increased 1.2–4.4 fold compared to
those before implantation. The expression levels of TLR4, TLR5, C3 and
CR1 were similar between both biopsies, and levels of C4, BCL2 and the
complement regulators (CD46, CD55, and CD59) were slightly de-
creased during AR (Fig. 2). Patients whose C3 expression increased
between AR and pre-transplantation did not differ from patients whose
C3 expression decreased in this time interval with respect to incidence
of steroid resistant rejection and death censored graft survival (data not
show).
3.4. Gene expression correlated with inflammatory cell markers and Banff
score
Since all TLRs showed elevated levels during AR, we investigated
whether this upregulation could be ascribed to infiltration of in-
flammatory cells. Correlations of innate immunity expression levels
with expression of key inflammatory markers (CD163, CD68, CD20,
CD3e) and Banff classification are summarized in Table S2. Except for
TLR2, TLR3 and TLR5, all TLRs correlated with one or more in-
flammatory cell marker. C2 and C3 were significantly correlated with
macrophage makers, whereas CD46 and CD59 showed a negative re-
lationship with these molecules. In addition, CR1 demonstrated
Table 2
Association between donor type, DGF, and gene expression in the pre-transplant tissues.a
Living (N=11) Deceased (N=66) P DGF (N=22) No DGF (N=44) Pf
TLR1 1.0 (0.86–1.95) 1.45 (0.90–2.06) 0.25 1.05 (0.61–1.56) 1.0 (0.65–1.42) 0.72
TLR2 1.0 (0.38–1.65) 1.42 (0.76–2.38)b 0.05 1.10 (0.69–1.87) 1.0 (0.56–1.80)b 0.73
TLR3 1.0 (0.79–1.55) 1.28 (0.95–1.66) b 0.30 0.99 (0.68–1.55) 1.0 (0.75–1.28)b 0.9
TLR4 1.0 (0.69–1.19) 0.96 (0.64–1.34) 0.69 1.25 (0.83–1.65) 1.0 (0.70–1.44) 0.17
TLR5 1.0 (0.82–2.29) 1.20 (0.67–1.89) b 0.58 1.45 (0.56–2.05) 1.0 (0.70–1.88)b 0.43
TLR6 1.0 (0.48–2.17) 1.26 (0.70–2.49) b 0.50 1.14 (0.63–2.29) 1.0 (0.54–2.08)b 0.69
TLR7 1.0 (0.64–2.03) 1.68 (1.05–3.07) c 0.03 0.86 (0.46–2.05) 1.0 (0.67–1.51)c 0.73
TLR8 1.0 (0.62–2.47) 1.49 (0.81–2.45)e 0.63 1.53 (1.01–2.76)b 1.0 (0.59–2.02)d 0.1
TLR9 1.0 (0.82–2.70) 1.00 (0.38–3.13)b 0.80 1.19 (0.38–3.68)b 1.0 (0.54–3.15) 0.9
TLR10 1.0 (0.44–4.29) 2.14 (0.72–6.42)c 0.29 0.90 (0.29–2.54)b 1.0 (0.31–3.87)b 0.74
CD46 1.0 (0.94–1.15) 0.86 (0.67–1.06) 0.02 0.90 (0.72–1.18) 1.0 (0.77–1.21) 0.45
CD55 1.0 (0.92–1.50) 0.90 (0.63–1.32) 0.09 1.06 (0.84–1.55) 1.0 (0.72–1.53) 0.36
CD59 1.0 (0.83–1.16) 0.97 (0.85–1.26) 0.61 0.99 (0.89–1.25) 1.0 (0.87–1.29) 0.74
C2 1.0 (0.38–1.28) 4.28 (1.81–6.81) 5.20E-6⁎ 1.01 (0.40–1.72) 1.0 (0.48–1.58) 0.95
C3 1.0 (0.83–1.52) 5.81 (2.88–14.43) 5.98E-6⁎ 1.21 (0.74–2.09) 1.0 (0.47–2.97) 0.59
C4 1.0 (0.89–1.65) 2.17 (1.38–3.03) 0.01 0.97 (0.53–1.39) 1.0 (0.70–1.38) 0.53
CR1 1.0 (0.75–2.07) 0.99 (0.67–1.54)b 0.60 1.26 (0.89–1.82) 1.0 (0.68–1.81)b 0.41
Bcl2 1.0 (0.87–1.49) 0.71 (0.47–1.01) 2.35E-3⁎ 1.11 (0.66–1.66) 1.0 (0.74–1.37) 0.61
BAX 1.0 (0.83–1.24) 1.18 (0.99–1.53) 0.12 1.13 (1.00–1.58) 1.0 (0.85–1.38) 0.13
BAX:BCL2 1.0 (0.80–1.18) 1.78 (1.50–2.34) 8.41E-5⁎ 1.09 (0.89–1.42) 1.0 (0.87–1.30) 0.34
a Gene expression data shown as medians with interquartile range.
b Data missing for one patients.
c Data missing for two patients.
d Data missing for four patients.
e Data missing for five patients.
f The expression level of patients with and without DGF was analyzed in the deceased donor group.
⁎ Statistically significant p-values after Bonferroni correction (P < 0.0025). P values were calculated by Mann-Whitney U tests (two-sided).
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relationships with T cell, B cell, macrophage markers, and interstitial
inflammation score. Apoptosis-related genes did not correlate with any
of the inflammatory molecules. In summary, the altered gene expres-
sion may in part be the result of infiltrating inflammatory cells.
3.5. High expression of TLR4 and high BAX:BCL2 ratio during AR predicts
inferior graft outcome
The relative expression of TLR4 at the moment of AR in living and
deceased patients was comparable. The patients with a deceased donor
graft were divided into two groups based on their gene expression le-
vels. One-third of patients who showed the highest TLR4 expression
were defined as high expression group (open circles); and the rest of
patients as low expression group (black dots) (Fig. 3A). At 12.5 years
post transplantation, patients with high TLR4 expression showed sig-
nificant inferior graft survival (59.2%) compared to recipients who had
relative low TLR4 expression (79.6%, P= 0.04, Fig. 3A).> 10% of the
patients with high TLR4 expression lost their graft within the first
3 months.
As for the BAX:BCL2 ratio: patients in the deceased donor group,
who had a BAX:BCL2 ratio that was higher than in the living donation
group, were defined as the high ratio group (open circles) (Fig. 3B). The
group of patients with relatively high BAX:BCL2 ratio at time of AR had
an inferior graft survival (57.9%) compared to patients with a low
BAX:BCL2 ratio (79.8%) and those with a living donor graft (88.3%,
P= 0.03, Fig. 3B). In univariate analysis, Banff classification score did
not predict long term graft survival. In multivariate cox regression
analysis within deceased donor group (Table 4), only high TLR4 ex-
pression (HR=3.46; CI= 1.17–10.23; P=0.025) and a high
BAX:BCL2 ratio (HR=4.6; CI= 1.44–14.73; P=0.01) were a sig-
nificant independent risk factor for graft loss. The penalized cox re-
gression model using the lasso showed that high TLR4 expression,
higher donor age (> 50 year) and high BAX:BCL2 ratio were the most
significant (Fig. S1). Expression levels in the pre-transplant tissues were
not associated with graft survival.
3.6. Localization of TLR4, TLR9, and BCL2 expression in renal transplant
biopsies
To verify clinically relevant mRNA markers at the protein level and
localize their expression in the tissue, immunohistochemical staining
for TLR4, BAX and BCL2 were performed on kidney biopsy specimens
(Fig. 4). In addition, we investigated TLR9 which was increased during
AR, and which has been shown to be an inducer of proinflammatory
signals [32]. Quantification of BAX expression could not be performed
since almost no staining was observed in the biopsies (positive
area < 10%). TLR4 protein expression was detected in tubular epi-
thelial cells and in inflammatory cells (Fig. 4A and B). Semi-quantita-
tive scoring showed a significantly higher expression during AR than
those with stable graft function. Protein expression of TLR9 was pre-
dominantly seen in tubular epithelial cells and varied considerably
within the AR group (Fig. 4C and D). BCL2 expression was observed in
the cytoplasm of tubular epithelial cells and in infiltrating in-
flammatory cells, and showed a wide range of expression among AR




























Fig. 1. Gene profiling in living and deceased donors at pre-
transplant (PreTx). The relative expression of C2 and C3
was significantly lower in living donor than that in de-
ceased donor in pre-transplant biopsies. The BAX:BCL2
ratio was significant lower in living donors in the PreTx
biopsies. Flags show median with interquartile range. P
values were calculated by Mann-Whitney U tests (two-
sided), ****P < 0.0001. (corrected for Bonferroni).
Table 3
Pairwise comparison of gene expression between pre-transplant and AR biopsies.
Pre-transplant (N=75) Acute rejection (N=75) P
TLR1 1.0 (0.65–1.46) 4.36 (3.24–5.34) 5.50E-14⁎
TLR2 1.0 (0.52–1.63) 3.42 (2.63–5.21) 4.60E-12⁎
TLR3 1.0 (0.74–1.29)a 1.42 (1.20–1.86)a 5.38E-8⁎
TLR4 1.0 (0.70–1.37) 1.21 (0.95–1.56) 0.019
TLR5 1.0 (0.56–1.59) 1.40 (1.01–1.70) 0.0028
TLR6 1.0 (0.56–1.97) 5.59 (4.18–8.47) 2.22E-13⁎
TLR7 1.0 (0.61–1.55)a 7.40 (4.60–9.79)a 1.48E-13⁎
TLR8 1.0 (0.57–1.73)b 27.04 (18.94–34.87)b 3.56E-13⁎
TLR9 1.0 (0.39–3.07)a 7.66 (4.99–13.14)a 1.62E-11⁎
TLR10 1.0 (0.31–2.83)c 8.96 (4.55–14.31)c 2.25E-9⁎
CD46 1.0 (0.78–1.22) 0.80 (0.62–1.07) 2.19E-3⁎
CD55 1.0 (0.71–1.48) 0.72 (0.58–0.84) 4.34E-7⁎
CD59 1.0 (0.86–1.25) 0.84 (0.63–1.04) 4.92E-4⁎
C2 1.0 (0.47–1.76) 2.49 (1.71–3.56) 4.34E-7⁎
C3 1.0 (0.43–2.35) 2.04 (1.32–3.65) 8.41E-3
C4 1.0 (0.65–1.44) 0.49 (0.36–0.61) 2.19E-10⁎
CR1 1.0 (0.70–1.54) 1.26 (0.87–1.97) 0.0087
BCL2 1.0 (0.67–1.35)c 0.76 (0.60–1.06)c 3.14E-4⁎
BAX 1.0 (0.84–1.31)c 0.98 (0.85–1.27)c 0.44
BAX:BCL2 1.0 (0.76–1.30)c 1.24 (0.95–1.49)c 6.20E-5⁎
a Data missing for one patients.
b Data missing for five patients.
c Data missing for two patients.
⁎ Statistically significant p-values based on Bonferroni correction (P < 0.0025), P
values were calculated by Wilcoxon signed ranks test.
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BCL2 and TLR9 during AR was increased in comparison to the stable
graft group, however this difference was not significant after correction
for multiple comparisons (Table 5).
4. Discussion
In the present study mRNA expression levels of TLRs, key comple-
ment components and regulators, and apoptosis-related genes were
investigated in biopsies obtained before graft implantation and at time
of AR. We found that in deceased donors, C2 and C3 expression and
BAX:BCL2 ratio are already elevated before transplantation but were
not indicative of DGF. High TLR4 levels and a high BAX:BCL2 ratio at
the time of an AR were both independent risk factors of graft loss.
Results from this exploratory study suggest that innate immune acti-






































































Fig. 2. Gene expression dynamics in kidney biopsies. The paired pre-transplant (PreTx) and acute rejection (AR) biopsies of 75 patients were used for comparison. The mRNA levels were






































































0.0 2.5 5.0 7.5 10.0 12.5
Time after transplantation (years)
Number at risk:
Low 61 54 41 26 19 5
High 30 24 17 12 9 2
Living 24 23 16 9 6 3
0.0 2.5 5.0 7.5 10.0 12.5
Time after transplantation (years)
Number at risk:
Low 72 64 46 32 25 6
High 14 10 9 4 3 1














Fig. 3. Association between gene expression at moment of acute rejection and kidney graft survival. (A) The TLR4-high expression patient group (n=30; dash line) had significantly
inferior graft survival compared to the TLR4-low expression patient group (n= 61; solid line) and living donor group (n=24; dots line). (B) The high BAX:BCL2 ratio patient group
(n=14; dash line) had significantly inferior graft survival rate compared to the low BAX:BCL2 ratio patient group (n= 72; solid line) and the living donor group (n= 23; dots line).
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Table 4
Cox regression analysis of transplant-related risk factors and post-transplant gene expression levels at time of AR with death censored graft survival.
Univariate Multivariate
HR (Lower-Upper) P HR (Lower-Upper) P
Recipient age (> 50 year) 1.35 (0.50–3.60) 0.55
Transplantation date (< 1999) 0.93 (0.25–3.42) 0.91
Donor age (> 50 year) 2.10 (0.78–5.68) 0.14
ABDR mismatching 0.95 (0.27–3.34) 0.94
Cold ischemia time (> 18 h) 0.88 (0.25–3.14) 0.85
Delayed graft function 1.61 (0.60–4.33) 0.35
Vascular rejection 1.28 (0.46–3.54) 0.63
Steroid resistant 1.94 (0.72–5.21) 0.19
Number of transplants (> 1) 2.88 (1.00–8.32) 0.05⁎ –
CD163 (high expression level) 1.52 (0.55–4.20) 0.42
CD68 (high expression level) 1.78 (0.62–5.07) 0.28
CD20 (high expression level) 0.42 (0.12–1.47) 0.17
CD3e (high expression level) 1.14 (0.41–3.16) 0.8
TLR4 (high expression level) 2.89 (1.08–7.78) 0.04⁎ 3.46 (1.17–10.23) 0.025⁎
Ratio BAX:BCL2 (higher than living) 3.22 (1.09–9.51) 0.03⁎ 4.60 (1.44–14.73) 0.01⁎






Fig. 4. Immunohistochemical staining pattern of TLR4, TLR9, and BCL2 in kidney transplant biopsy specimens. TLR4 protein expression was detected in tubular epithelial cells and in
inflammatory cells (A–B). TLR9 was observed in the tubular epithelial cells (C–D). BCL2 was detected in tubular epithelial cells and infiltrated lymphocytes (E–F). Both BCL2 and TLR9
expression varied extensively between acute rejection biopsy specimens. Two representative samples from the acute rejection group are shown.
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Although the TLR/MyD88 pathway was found to be redundant for
host defense against most natural infections [33], depletion of a func-
tional TLR pathway in mice, by knocking out either TLR2, TLR4 or
MyD88, protects against IRI and kidney dysfunction, and limits an in-
crease in expression of cytokines, chemokines and in infiltration of in-
flammatory cells [34,35]. In human kidney transplants, the expression
of TLR4 and HMGB1 (an endogenous ligand of TLR4) was significantly
elevated in pre-implementation biopsies from deceased donors in con-
trast to those from living donors [11]. However, in our study, we could
not confirm these findings (Table 2), and none of the markers we in-
vestigated were associated with DGF.
Earlier studies showed that the expression of TLRs is significantly
upregulated during allograft rejection mainly because of infiltration of
leukocytes [13,36]. However, none of the previous studies have docu-
mented gene expression dynamics in a large patient cohort. We showed
that the expression of all TLRs except TLR4 and TLR5 was significantly
increased in AR biopsies when compared to pre-implementation biop-
sies (Table 3). Moreover, expression of majority of the TLRs positively
correlated with one or more inflammatory cell markers at the moment
of AR (Table S1), suggesting that the elevated expression of TLRs is a
result of inflammatory cell presence. As for TLR2 and TLR3, which
showed only minor increase during an AR but they were not correlated
with any inflammatory markers, their expression may be dominant in
renal parenchymal tissue. Similar expression patterns of TLR3 were
reported by Dessing et al. [36]. TLR4, the expression of which corre-
lated with CD163 and CD68 but was not increased during AR, may be
expressed by both parenchymal and myeloid cells. In addition, patients
with relatively high levels of TLR4 during AR exhibited inferior graft
survival 12.5 years after transplantation, which may mean that in-
tracellular ligands released after cell damage bind to TLR4 and thereby
provide additional inflammatory signals leading to long term graft loss.
Expression of TLR4 in the renal allograft biopsy has been described
previously [11,13]. TLR4 was expressed in tubular cells and infiltrated
lymphocytes, with significantly higher expression during AR compared
to stable graft conditions. The possible explanation, that on one hand no
increase in TLR4 mRNA was seen between AR and pre-Tx and on the
other hand immunohistochemistry showed significantly higher ex-
pression during AR compared to stable graft conditions, may be that the
epithelium expresses high levels of mRNA but relatively low level of
protein. The endogenous pattern recognition receptor TLR9 is involved
in immune complex kidney disease [37]. Immunohistochemical
staining showed that TLR9 was increased during AR compared to the
stable graft group with borderline significance.
The complement system acts as a bridge to the adaptive system and
facilitates clearance of immune complexes and cellular debris. It has
been shown that the MAC plays a central role in renal IRI and that
locally synthesized C3 is important in kidney graft survival [17,38]. In
line with a previous study [14], the mRNA levels of C2 and C3 in the
living donor grafts were significantly lower than those in the deceased
donor grafts at time of implantation, which supports the notion that the
local C3 expression is induced by donor brain death [15]. The ob-
servations of a slight increase in C4 expression in deceased donors are
in line with those from a previous study [14]. However, inconsistent
with that study, the expression level of CR1 was comparable between
deceased and living donor biopsies in our relatively large cohort. The
increased C2 during AR may represent a higher activity of the classical
and lectin pathway, whereas the decreased C4 expression may be a
result of injury of renal parenchymal cells.
The complement regulators CD46, CD55, and CD59 act as inhibitors
of activation of the complement pathway. Hyper-sensitized rats treated
with sCR1 displayed significantly prolonged cardiac graft survival [39].
Similarly, kidneys of animals treated with CR1 derivatives (APT070)
showed less acute tubular injury, and the animals had a significantly
higher graft survival rate [40]. CD55 had a protective effect on renal
function in C4d-negative grafts and antibody-mediated cardiac allograft
rejection [22,41]. We found that expression of CD46, CD55 and CD59
was significantly reduced during an AR compared to that in the pre-
transplantation tissue. However, none of the complement regulators
were predictive for the development of DGF, steroid resistant rejection
and graft survival in the present study. Interestingly, Budding et al.
showed that serum sCD59 are elevated at the time of bronchiolitis
obliterans syndrome (BOS) after lung transplantation, and the patients
with higher serum sCD59 titers (> 400 pg/mL) had a significantly
lower chance of BOS free survival. We observed that the expression of
complement regulators at time of AR was slightly decreased compared
to pre-transplant conditions, and that it negatively correlated with ex-
pression of macrophage markers.
It has been shown that kidney cell apoptosis is involved in IRI and
that apoptotic cells are frequently present in AR biopsies [23,24]. In the
present study, the mRNA of BCL2, an anti-apoptotic molecule, was
lower in deceased donor biopsies than in living donor grafts. The higher
BAX:BCL2 ratio suggests that the extent of apoptosis is already in-
creased in deceased donors. The BAX:BCL2 ratio tended to be higher in
the DGF group in the deceased donor cohort, but this was only marginal
(Table 2), which is inconsistent with findings from a previous study
[27]. During an AR, the BAX:BCL2 ratio was marginally increased and it
significantly correlated with expression of macrophage markers. Pro-
tein investigations by immunohistochemical staining showed that BAX
was rarely detected in the biopsy samples. The BCL2 expression was
mainly observed in tubular epithelial cell and inflammatory cells, with
a wide range of staining within the AR group. Patients who received a
living donor graft had superior graft survival compared to those with a
graft from a deceased donor, and thus this group acted as a reference.
Moreover, patients with relatively high BAX:BCL2 ratio during AR in
their deceased donor graft demonstrated significantly inferior graft
survival rates (57.9%) 12.5 years after transplantation compared to
those with a lower ratio or to patients who had received a living donor
graft (Fig. 3). High BAX:BCL2 ratio during AR possibly reflects an in-
creased number of apoptotic cells, which leads to attraction of phago-
cytic cells to the graft [42,43]. The accumulated phagocytes may be
triggered by immunogenic danger signals and mediate subsequent
chronic allograft loss [44,45].
In conclusion, complement and apoptosis pathways are elevated
before kidney transplantation. Increased expression of the majority of
genes partly reflect the infiltration of inflammatory cells during an AR.
Relatively high TLR4 expression and BAX:BCL2 ratio during AR, pos-
sibly reflecting enhanced immunogenic danger signals, were both in-
dependent risk factors for adverse outcome after transplantation of a
deceased donor kidney. The results of this study suggest that the dif-
ferent impact of AR on outcome between living and deceased donor
transplants may partly be ascribed to differences in TLR4 regulation
and cell death related mechanisms. They form a basis to further validate
and explore the functional relevance of these pathways in relation to
transplant outcome.
Supplementary data to this article can be found online at https://
Table 5
Immunohistochemical scoring of TLR4, TLR9, and BCL2 in stable graft function and acute
rejection biopsies.
IHC score 1 2 3 4 5 P
TLR9 0.069
SGF 1 5 1 0 0
AR 4 4 7 4 4
TLR4 0.008⁎
SGF 4 2 1 0 0
AR 2 7 5 5 3
BCL2 0.024
SGF 1 3 2 1 0
AR 0 3 8 8 3
IHC, Immunohistochemistry; SGF, stable graft function; AR, acute rejection.
⁎ Statistically significant p-values based on Bonferroni correction (P < 0.016), P va-
lues were calculated by Mann-Whitney Test.
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